Rapid Home Diagnostic for IBD with Integrated Care App
Rapid Inflammatory Bowel Disease (IBD) Diagnostic
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
The University of Sydney has developed a rapid diagnostic platform for Inflammatory Bowel Disease (IBD) that measures myeloperoxidase (MPO) activity in faecal samples. This test provides results within 5 minutes, making it suitable for home use and addressing patient anxiety by offering real-time disease monitoring. Unlike conventional Calprotectin assays, it eliminates the delays associated with lab analysis and enables integrated care through an app for patients and clinicians. The platform enhances diagnostic accuracy, differentiates IBD subtypes, and supports personalized treatment plans. This technology bridges the gap between at-home monitoring and professional healthcare, enabling timely therapeutic adjustments.
IP Type or Form Factor: Patent Pending; Platform; Device
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Healthcare Consumer
